See more : Nihon Kohden Corporation (NHNKY) Income Statement Analysis – Financial Results
Complete financial analysis of AEON Biopharma, Inc. (AEON) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of AEON Biopharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Anhui Heli Co.,Ltd. (600761.SS) Income Statement Analysis – Financial Results
- Axman Enterprise Co., Ltd. (6804.TWO) Income Statement Analysis – Financial Results
- Shenzhen Textile (Holdings) Co., Ltd. (200045.SZ) Income Statement Analysis – Financial Results
- Consolidated Construction Consortium Limited (CCCL.NS) Income Statement Analysis – Financial Results
- Newron Pharmaceuticals S.p.A. (0QOI.L) Income Statement Analysis – Financial Results
AEON Biopharma, Inc. (AEON)
About AEON Biopharma, Inc.
AEON Biopharma, Inc., a biopharmaceutical company, focuses on the development botulinum toxins for the treatment of debilitating medical conditions. It also develops 900 kDabotulinum toxin complex, ABP-450, for migraine, cervical dystonia, and gastroparesis. The company was formerly known as ALPHAEON Corporation and changed its name to AEON Biopharma, Inc. in December 2019. AEON Biopharma, Inc. was incorporated in 2012 and is headquartered in Newport Beach, California.
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 2.52M | 3.36M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 1.00K |
| Gross Profit | 0.00 | 0.00 | 2.52M | 3.36M |
| Gross Profit Ratio | 0.00% | 0.00% | 100.00% | 99.97% |
| Research & Development | 34.75M | 25.73M | 7.32M | 4.81M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 13.68M | 11.15M | 11.59M | 46.04M |
| Other Expenses | 0.00 | 10.21M | -5.61M | -10.75M |
| Operating Expenses | 48.43M | 36.88M | 18.91M | 51.73M |
| Cost & Expenses | 48.43M | 36.88M | 18.91M | 51.73M |
| Interest Income | 0.00 | 0.00 | 0.00 | 720.00K |
| Interest Expense | 0.00 | 0.00 | 15.00K | 7.47M |
| Depreciation & Amortization | 68.00K | 3.00K | -5.75M | 1.26M |
| EBITDA | -48.36M | -7.91M | -22.14M | -50.41M |
| EBITDA Ratio | 0.00% | 0.00% | -879.35% | -1,501.61% |
| Operating Income | -48.43M | -65.85M | -16.39M | -53.97M |
| Operating Income Ratio | 0.00% | 0.00% | -650.83% | -1,607.57% |
| Total Other Income/Expenses | -4.13M | 10.21M | -16.53M | 199.64M |
| Income Before Tax | -52.56M | -55.64M | -32.91M | 145.67M |
| Income Before Tax Ratio | 0.00% | 0.00% | -1,307.11% | 4,339.29% |
| Income Tax Expense | -160.49K | 28.97M | 15.00K | -14.65M |
| Net Income | -52.56M | -55.64M | -32.91M | 172.92M |
| Net Income Ratio | 0.00% | 0.00% | -1,307.11% | 5,151.03% |
| EPS | 0.00 | -2.53 | -2.22 | 11.69 |
| EPS Diluted | 0.00 | -2.53 | -2.22 | 11.69 |
| Weighted Avg Shares Out | 0.00 | 22.00M | 14.80M | 14.80M |
| Weighted Avg Shares Out (Dil) | 0.00 | 22.00M | 14.80M | 14.80M |
AEON Biopharma Presents Positive Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia at the International Parkinson and Movement Disorders Society Congress®
AEON Biopharma Receives Notice of Allowance from USPTO for a Patent Covering Use of Botulinum Toxins to Treat Migraine Headache
Strathspey Crown Holdings Group, LLC Provides Clarifying Statement Regarding Form 4 Filing with SEC for Holdings in AEON Biopharma
Atalaya Capital Management LP Acquires New Stake in AEON Biopharma Inc
Priveterra Acquisition says it will list on NYSE after AEON combination
Source: https://incomestatements.info
Category: Stock Reports